Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHD

DALLAS/FORT WORTH, Texas, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news